In the rapidly evolving field of biopharmaceutical manufacturing, innovations in mycoplasma and sterility testing are becoming paramount for ensuring product safety and efficacy. Applied Biosystems™ MycoSEQ™ Plus system and the Applied Biosystems™ SteriSEQ™ Rapid Sterility Testing System, both developed by Thermo Fisher Scientific, are at the forefront of these advancements. These groundbreaking technologies are specifically designed to streamline testing workflows for cell therapy products, facilitating faster detection and quicker turnaround times. By speeding up these critical processes, these systems play a significant role in the timely delivery of life-saving therapies to patients, which is essential in the competitive and time-sensitive arena of cell therapy manufacturing.
The MycoSEQ™ Plus system stands out for its highly sensitive and specific detection of mycoplasma contamination. Mycoplasma, a type of bacteria that lacks a cell wall, notoriously evades standard sterilization techniques and poses severe risks to cell cultures. Detecting these contaminants swiftly is crucial for maintaining the integrity and purity of cell therapy products. Meanwhile, the SteriSEQ™ Rapid Sterility Testing System addresses another critical challenge faced by biopharmaceutical manufacturers—ensuring that products remain sterile throughout the production process. This rapid sterility testing system significantly reduces the time required to confirm sterility, thus enhancing manufacturing efficiency without compromising safety.
New Paradigm in Cell Therapy Manufacturing
In the swiftly advancing world of biopharmaceutical manufacturing, innovations in mycoplasma and sterility testing are crucial for guaranteeing product safety and effectiveness. Thermo Fisher Scientific leads these advancements with its Applied Biosystems™ MycoSEQ™ Plus system and SteriSEQ™ Rapid Sterility Testing System. These technologies are engineered to optimize testing workflows for cell therapy products, allowing for faster detection and quicker turnaround times. By expediting these essential processes, the systems are vital in the prompt delivery of life-saving therapies, pivotal in the competitive and urgent field of cell therapy manufacturing.
The MycoSEQ™ Plus system is notable for its highly sensitive and specific detection of mycoplasma contamination. Mycoplasma, a bacteria lacking a cell wall, often eludes conventional sterilization methods and threatens cell cultures. Prompt detection of these contaminants is critical for maintaining the integrity and purity of cell therapy products. On the other hand, the SteriSEQ™ Rapid Sterility Testing System tackles the challenge of ensuring product sterility throughout production. This system drastically reduces the time needed to confirm sterility, enhancing manufacturing efficiency while maintaining safety.
